Noxopharm doses first patient in NOXCOVID-1 clinical trial with Veyonda
Australian drug development company Noxopharm has dosed the first patient in the phase 1 NOXCOVID-1 clinical trial with Veyonda, its lead pipeline candidate, in hospitalized COVID-19 patients. Veyonda is an experimental anti-cancer drug. It is being evaluated in the NOXCOVID-1 clinical trial in the treatment of hospitalized patients with moderate lung dysfunction, who need low […]